Startups
Minerva Biotechnologies is developing therapies for curing cancers and commercializing core technology that will enable next generation stem cell therapies. Both flow from Minerva’s fundamental discovery that both cancer cell and stem cell growth are mediated by the same two molecules: the growth factor NME-p and the growth factor receptor MUC1*.
-Cancer Therapeutics-
Minerva discovered that cancer cells are healthy cells that are being reprogrammed back to a stem cell state. We can reverse the reprogramming and make cancer cells differentiate so that cancer growth is turned off. This is a novel approach to curing cancer. We have 3 anti-cancer therapeutics in our pipeline.
-Regenerative Medicine-
Minerva is the first company to generate human naïve state induced pluripotent stem cells (iPS cells) using a single, naturally occurring human stem cell growth factor. These earlier stem cells have a clean slate, they are more easily directed to develop into functional mature cells, which could be used for transplant.
-Cancer Therapeutics-
Minerva discovered that cancer cells are healthy cells that are being reprogrammed back to a stem cell state. We can reverse the reprogramming and make cancer cells differentiate so that cancer growth is turned off. This is a novel approach to curing cancer. We have 3 anti-cancer therapeutics in our pipeline.
-Regenerative Medicine-
Minerva is the first company to generate human naïve state induced pluripotent stem cells (iPS cells) using a single, naturally occurring human stem cell growth factor. These earlier stem cells have a clean slate, they are more easily directed to develop into functional mature cells, which could be used for transplant.
Overview
Location
United States, Massachusetts, Waltham
Employees
11-50
Phone
+1 781-487-0200
Founded date
1999
Mentions in press and media 4
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Jan 31, 2008 | Biochip and stem-cell biotech Minerva fires, sues its CEO | A potentially interesting legal drama is unfolding at Minerva Biotechnologies, a Waltham, Mass., startup developing biochips and exploring the biology of cancer stem cells. In a terse release, the company said it has terminated CEO Jim Czir... |
| Funding Roundup: Which biotech, medtech and healthIT startups got investments this week? | Each week, many millions are invested into life sciences startups. There are so many that often, they get lost in the weeds. We’re keeping track for you – based on regulatory filings reported to the SEC. Here are the new funding notices fro... | |
| Minerva Biotechnologies | “Minerva Biotechnologies is developing therapies for curing cancers and commercializing core technology that will enable next generation stem cell therapies.” |
Reviews 0
FAQ about Minerva Biotechnologies
When was Minerva Biotechnologies founded?
Minerva Biotechnologies was founded in 1999.
What has the press written about Minerva Biotechnologies?
Parsers VC has collected 4 articles mentioning Minerva Biotechnologies, among them “Biochip and stem-cell biotech Minerva fires, sues its CEO” (Jan 31, 2008) and “Funding Roundup: Which biotech, medtech and healthIT startups got investments this week?”.
Is Minerva Biotechnologies still active?
Yes, Minerva Biotechnologies is active; its latest activity on Parsers VC dates from Oct 31, 2014.